Latest / Oncology Data Advisor
Cabozantinib/Atezolizumab for Metastatic Colorectal Cancer: Thomas Abrams, MD
In this interview, Dr. Thomas Abrams of Harvard Medical School discusses the role that cabozantinib/atezolizumab may play for patients with metastatic colorectal cancer, particularly those with RAS wild-type disease, in the coming years.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.